<DOC>
	<DOCNO>NCT02213913</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose lenalidomide give together combination chemotherapy see well work treat patient v-myc myelocytomatosis viral oncogene homolog ( avian ) ( MYC ) -associated B-cell lymphoma . Lenalidomide may stop growth B-cell lymphoma block growth new blood vessel necessary cancer growth block enzyme need cell growth . Biological therapy , lenalidomide , use substance make live organism may stimulate suppress immune system different way stop cancer cell grow . Drugs use chemotherapy , etoposide , prednisone , vincristine sulfate , doxorubicin hydrochloride , cyclophosphamide , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Monoclonal antibody , rituximab , may block cancer growth different way target certain cell . Giving lenalidomide together combination chemotherapy may effective treatment patient B-cell lymphoma .</brief_summary>
	<brief_title>Lenalidomide Combination Chemotherapy ( DA-EPOCH-R ) Treating Patients With MYC-Associated B-Cell Lymphomas</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) lenalidomide add dose-adjusted ( DA ) -etoposide , prednisone , vincristine sulfate , doxorubicin hydrochloride , cyclophosphamide , rituximab ( EPOCH-R ) ( hereby term `` DA-EPOCH-RR '' ) patient double hit lymphoma ( DHL ) lymphoma . ( Phase I ) II . To determine 1- 2-year progression free survival ( PFS ) DA-EPOCH-RR patient DHL lymphoma . ( Phase II ) SECONDARY OBJECTIVES : I . Overall response rate , complete response , duration response . II . Quality life ( QOL ) measure use standardize scale . III . Toxicity assessment use version 4.0 National Cancer Institute ( NCI ) -Common Terminology Criteria Adverse Events ( CTCAE ) criterion . IV . Overall survival ( OS ) 1 2 year . OUTLINE : This phase I , dose-escalation study lenalidomide follow phase II study . INDUCTION PHASE : Patients receive lenalidomide orally ( PO ) daily day 1-14 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . DA-EPOCH-R : Patients receive etoposide intravenously ( IV ) continuously day 1-4 , prednisone PO twice daily ( BID ) day 1-5 , vincristine sulfate IV continuously day 1-4 , doxorubicin hydrochloride IV continuously day 1-4 , cyclophosphamide IV 15 minute day 5 , rituximab IV 4 hour day 1 ( per institutional guideline ) . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . CONSOLIDATION PHASE : Patients transplantation ( hematopoietic stem cell transplant [ HSCT ] ) -eligible receive BCNU , etoposide , cytarabine , melphalan ( BEAM ) -conditioning regimen follow autologous ( auto ) -HSCT HSCT discretion treat physician . Patients undergo HSCT first remission receive lenalidomide maintenance 12 month . After completion study treatment , patient follow every 3 month 1 year , every 4 month 1 year , periodically 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Inclusion Criteria 1 . Bcell lymphoma comprehensive immunohistochemistry ( IHC ) panel establish lineage ( CD20 , CD3 ) cell origin ( CD10 , BCL6 MUM1 ) addition proliferative/prognostic marker ( Ki67 , Cmyc BCL2 ) . DHL identify use cytogenetics and/or immunohistochemistry detail section 4.1.2 . 2 . To define DHL , patient must evidence Cmyc [ define : Cytogenetic evidence ( FISH karyotype ) Cmyc break ( Increased copy number consider positivity Cmyc ) OR Positive IHC define &gt; 40 % lymphoma cell stain Cmyc ] PLUS either : 1 . Breaks BCL2 via cytogenetic study 2 . BCL2 immunopositivity &gt; 70 % lymphoma cell . 3 . Patients allow received radiotherapy enrollment radiation give alleviate pain and/or neurologic compromise long remain area measurable disease present . Further , investigator 's discretion patient unstable , one cycle RCHOP allow prior enrollment one cycle . For purpose trial , prednisone corticosteroid use nonlymphomatous condition allow . In addition , prior/recent short course ( &lt; 2 week ) steroid symptom relief lymphomarelated symptom allow . 4 . AST ALT &lt; 3 x upper limit normal ( ULN ) , total bilirubin &lt; 1.5 x ULN ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver involvement NHL stable chronic liver disease per investigator assessment ) . 5 . Patients must adequate renal function virtue GFR &gt; 50 ml/minute use CockroftGault formula . 6 . Patients must adequate bone marrow function ( platelet &gt; 100,000 ANC &gt; 1,200 ) . Patients bone marrow involvement allow investigator 's discretion regardless cytopenia . 7 . ECOG PS 02 . 8 . Age ≥ 18 year . 9 . All study participant must register mandatory lenalidomide REMS® program , willing able comply requirement REMS® program . 10 . Females reproductive potential must adhere scheduled pregnancy test require lenalidomide REMS® program . ( Please see study schema detail ) 11 . Able take aspirin ( 81 325 mg ) daily prophylactic anticoagulation ( patient intolerant ASA may use warfarin low molecular weight heparin ) . 12 . Ability read , understand , sign write informed consent approve institutional IRB . Alternatively , patient legal guardian read , understand , sign write informed consent may also enroll . Exclusion Criteria 1 . Prior therapy lymphoma 2 . Known CNS involvement 3 . Known HIV positive status 4 . Pregnant females 5 . Burkitt and/or precursor lymphoblastic leukemia/lymphoma . 6 . Prior pomalidomide exposure 7 . Known hypersensitivity lenalidomide thalidomide 8 . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . 9 . Subjects currently active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver involvement NHL stable chronic liver disease per investigator assessment ) . 10 . Treatment known nonmarketed drug substance experimental therapy within 4 week prior enrollment , currently participate interventional clinical study NHL illness ( except observational , prevention , and/or registry trial ) . 11 . No current malignancy . Subjects free malignancy least 2 year , history completely resect nonmelanoma skin cancer , successfully treat situ carcinoma ( site ) eligible . Women history cervical cancer allow . 12 . Chronic current infectious disease require systemic antibiotic , antifungal , antiviral treatment , limited , chronic renal infection , chronic chest infection bronchiectasis , tuberculosis active Hepatitis C. 13 . History significant cerebrovascular disease past 3 month ongoing event active symptom sequela . 14 . Positive serology Hepatitis B ( HB ) define positive test HBsAg . In addition , negative HBsAg HBcAb positive ( regardless HBsAb status ) , HB DNA test perform positive , subject exclude unable tolerate and/or receive antiHepatitisB therapy . Positive serology prior vaccination allow . 15 . Positive serology hepatitis C ( HC ) define positive test HCAb . 16 . Inability comply study followup test procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>